<DOC>
	<DOC>NCT02764671</DOC>
	<brief_summary>The purpose of this study is to further evaluate the immunogenicity and safety of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates.</brief_summary>
	<brief_title>Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who are healthy fullterm infants after birth, Apgar score ≥8; Subjects with a birth weight ≥ 2500g; Subjects' guardians are able to understand and sign informed consent; Subjects who can and will comply with the requirements of the protocol. Family history of eclampsia, epilepsy and encephalopathy; Subjects' birth mother had immune system dysfunction, or history of organ transplantation or blood dialysis; Subjects' parents had a medical history of allergic to any ingredient of the vaccine, including supplementary material and formaldehyde; Subjects' parents had a medical history of allergic to combined hepatitis A and B vaccine(HAB) or hepatitis B vaccine; Subjects had serious acute and chronic diseases; with temperature ≧37.1℃; Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>recombinant hepatitis B vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>